Clinical Research Directory

Inclusion Criteria: * At least 18 years old * Diagnosis of rheumatoid arthritis as defined by ACR/EULAR 2010 classification criteria * A positive test result for Rheumatoid Factor (RF) \> 14 IU/mL and/or Anti-Citrullinated Protein Antibodies (Anti-CCP) ≥ 20 U/mL * At least moderate disease activity, defined as DAS28-CRP \> 3.8 and at least 4/28 tender and 4/28 swollen joints at the screening and baseline visits * High sensitivity CRP (hsCRP) ≥ 10 mg/L at the screening and baseline visits * On stable dose of background DMARD therapy (see exclusion criteria) * Able and willing to comply with all study-related procedures, including at-home device use, daily treatment, scheduled visits, and assessments Exclusion Criteria: * Unable to provide informed consent * Current or planned participation in another interventional clinical trial * Prior use of \> 2 biologic or targeted synthetic DMARDs for RA where the primary reason for discontinuation was efficacy * Conventional synthetic DMARDs: * Initiated within last 12 weeks or adjusted dose within 4 weeks prior to enrollment * Inability to maintain a stable dose during the study * Biologic DMARDs: * Initiated or dose-adjusted within 12 weeks prior to enrollment * Inability to maintain a stable dose during the study * JAK inhibitors: * Use within 4 weeks prior to enrollment or expected use during study participation * Corticosteroids: * Initiated or dose-adjusted within 4 weeks prior to enrollment * Current dose \> 10 mg/day prednisone (or equivalent) * Current tobacco or nicotine product use * Pregnant or planning to become pregnant during the study period * Known hypersensitivity to ultrasound gel or membrane components * Active bacterial, viral, or fungal infection * Receiving chemotherapy or immunotherapy for malignancy * History of splenic disorders, including splenectomy, congenital asplenia, or splenomegaly on screening ultrasound * Rash, wound, or skin infection overlying the spleen * History of vagal nerve injury, vagotomy, or known autonomic neuropathy * Recent abdominal surgery or trauma within 30 days of screening * Uncontrolled fibromyalgia or other diffuse pain syndromes that may confound symptom reporting